Pharma Mar, S.A. (PHMMF)

Market Cap	1.77B +2.4%
Revenue (ttm)	259.94M +26.6%
Net Income	88.04M +187.0%
EPS	5.05 +188.7%
Shares Out	n/a
PE Ratio	20.07
Forward PE	26.08
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,750
Average Volume	1,715
Open	92.19
Previous Close	88.72
Day's Range	92.19 - 92.19
52-Week Range	80.91 - 110.40
Beta	0.45
RSI	54.01
Earnings Date	Feb 27, 2026

About Pharma Mar

Pharma Mar, S.A., a biopharmaceutical company, focuses on the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, Germany, Ireland, France, Switzerland, rest of the European Union, the United States, and internationally. It operates through Oncology and RNA Interference segments. The company offers Yondelis, a synthetic compound derived from the colonial sea squirt ecteinascidia turbinata that treats soft tissue sarcoma and ovarian cancer; Zepzelca, a synthetic compound designed to...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1986
• Employees: 505
• Stock Exchange: OTCMKTS
• Ticker Symbol: PHMMF

Financial Performance

In 2025, Pharma Mar's revenue was 221.39 million, an increase of 26.61% compared to the previous year's 174.86 million. Earnings were 74.99 million, an increase of 187.03%.

Financial numbers in EUR